Salute e Benessere
FMI Reports Strong 11.7% CAGR Growth Outlook for the GLP-1 Receptor Agonist Market Through 2035
Pharmaceutical manufacturers are rapidly advancing , , and to elevate patient adherence and treatment outcomes. The industry is experiencing:
"GLP-1 receptor agonists have evolved from single-indication diabetes drugs to multi-benefit metabolic therapies," said an FMI spokesperson. "Manufacturers investing in delivery innovation, stability optimization, and oral alternatives are expected to lead the next decade of growth."
Exenatide continues to command of the drug-class share, supported by its strong safety record, clinical familiarity, and availability in both short-acting and extended-release forms. Increasing generic penetration is unlocking new affordability and accessibility, enabling wider adoption in emerging markets.
Parenteral delivery remains the gold standard due to optimal bioavailability for peptide-based therapies. Manufacturers' ongoing advancements in and are expected to maintain the segment's leading position over the decade.
With nearly , the demand for GLP-1 receptor agonists continues to grow rapidly. Their proven efficacy in:
positions them as a cornerstone in modern diabetes treatment guidelines. Improved insurance coverage and early-diagnosis initiatives are driving prescription volumes across major markets
FMI's country-wise analysis shows exceptional growth potential:
With urbanization, lifestyle shifts, and healthcare reforms, China's diabetic population is among the world's largest. Accessibility to advanced GLP-1 therapies continues improving under government-led healthcare expansion.
India represents the world's fastest-growing metabolic medicine market. High genetic predisposition, rising obesity rates, and improved awareness of early diabetes management are generating extraordinary demand for GLP-1 therapies.
With a mature healthcare ecosystem, the UK continues to expand access through NHS coverage and proactive preventive-care programs.
Leading companies are focusing on clinical trials exploring cardiovascular outcomes, beta-cell preservation, and novel GLP-1/GLP-2 combinations. Major players include:
Despite strong momentum, FMI highlights several barriers:
FMI's GLP-1 Receptor Agonist Market Report covers:
Future Market Insights (FMI) is a leading provider of market intelligence, offering in-depth research across pharmaceuticals, healthcare, biotechnology, and life sciences. With a global research network and advanced analytical frameworks, FMI supports manufacturers, investors, policymakers, and stakeholders in making informed strategic decisions.
Logo: https://mma.prnewswire.com/media/1197648/3531122/FMI_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/fmi-reports-strong-11-7-cagr-growth-outlook-for-the-glp-1-receptor-agonist-market-through-2035--302631818.html